GoodRx (GDRX) 13G/A: Vanguard Reports 0 Shares
GoodRx Holdings Inc filing an amendment to a Schedule 13G/A reports that The Vanguard Group beneficially owns 0 shares (0%) of Common Stock as shown in the amendment dated 03/13/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
GoodRx Holdings Inc filing an amendment to a Schedule 13G/A reports that The Vanguard Group beneficially owns 0 shares (0%) of Common Stock as shown in the amendment dated 03/13/2026. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report ownership separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why does Vanguard report separate holdings in this Schedule 13G/A for GDRX?
Who signed the Schedule 13G/A amendment for Vanguard on GoodRx (GDRX)?
Does the filing identify any entity holding more than 5% of GoodRx common stock?
What address is listed for The Vanguard Group in the GoodRx Schedule 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.